FN2 Earnings Intelligence
ResMed Inc. financials
ResMed Inc. (RMD) financial statements and key operating metrics from FN2 Research.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 6/30/2021 | 6/30/2022 | 6/30/2023 | 6/30/2024 | 6/30/2025 | 6/30/2026 est. | 6/30/2027 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $295.3 | $273.7 | $227.9 | $238.4 | $1,209.4 | - | - |
| + Debt | $655.4 | $775.2 | $1,441.1 | $707.2 | $668.3 | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $3,196.8 | $3,578.1 | $4,223 | $4,685.3 | $5,146.3 | $5,649.9 | $5,945.3 |
| % Growth | 8.1% | 11.9% | 18.0% | 10.9% | 9.8% | 9.8% | 5.2% |
| Gross Profit | $1,839.1 | $2,024.3 | $2,355.7 | $2,655.3 | $3,055 | - | - |
| % Margin | 57.5% | 56.6% | 55.8% | 56.7% | 59.4% | - | - |
| EBITDA | $1,060.4 | $1,159.9 | $1,297 | $1,496.8 | $1,883.8 | - | - |
| % Margin | 33.2% | 32.4% | 30.7% | 31.9% | 36.6% | - | - |
| Net Income | $474.5 | $779.4 | $897.6 | $1,021 | $1,400.7 | - | - |
| % Margin | 14.8% | 21.8% | 21.3% | 21.8% | 27.2% | - | - |
| Diluted EPS | $3.24 | $5.30 | $6.09 | $6.92 | $9.51 | $11.13 | $12.06 |
| % Growth | -24.1% | 63.6% | 14.9% | 13.6% | 37.4% | 17.0% | 8.4% |
| Operating Cash Flow | $736.7 | $351.1 | $693.3 | $1,401.3 | $1,751.6 | - | - |
| CapEx | $102.7 | $134.8 | $119.7 | $99.5 | $89.9 | - | - |
| Free Cash Flow | $634 | $216.3 | $573.6 | $1,301.8 | $1,661.7 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 6/30/2021 | 6/30/2022 | 6/30/2023 | 6/30/2024 | 6/30/2025 | 6/30/2026 est. | 6/30/2027 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $3,196.8 | $3,578.1 | $4,223 | $4,685.3 | $5,146.3 | $5,649.9 | $5,945.3 |
| Gross Profit | $1,839.1 | $2,024.3 | $2,355.7 | $2,655.3 | $3,055 | - | - |
| EBITDA | $1,060.4 | $1,159.9 | $1,297 | $1,496.8 | $1,883.8 | - | - |
| Net Income | $474.5 | $779.4 | $897.6 | $1,021 | $1,400.7 | - | - |
| Diluted EPS | $3.24 | $5.30 | $6.09 | $6.92 | $9.51 | $11.13 | $12.06 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 6/30/2021 | 6/30/2022 | 6/30/2023 | 6/30/2024 | 6/30/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $295.3 | $273.7 | $227.9 | $238.4 | $1,209.4 |
| Short-term Debt | $12 | $9.9 | $9.9 | $9.9 | $9.9 |
| Long-term Debt | $643.4 | $765.3 | $1,431.2 | $697.3 | $658.4 |
| Total Debt | $655.4 | $775.2 | $1,441.1 | $707.2 | $668.3 |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 6/30/2021 | 6/30/2022 | 6/30/2023 | 6/30/2024 | 6/30/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $736.7 | $351.1 | $693.3 | $1,401.3 | $1,751.6 |
| Capital Expenditure | $102.7 | $134.8 | $119.7 | $99.5 | $89.9 |
| Free Cash Flow | $634 | $216.3 | $573.6 | $1,301.8 | $1,661.7 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 6/30/2021 | 6/30/2022 | 6/30/2023 | 6/30/2024 | 6/30/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 8.1% | 11.9% | 18.0% | 10.9% | 9.8% |
| Gross Margin | 57.5% | 56.6% | 55.8% | 56.7% | 59.4% |
| EBITDA Margin | 33.2% | 32.4% | 30.7% | 31.9% | 36.6% |
| Net Margin | 14.8% | 21.8% | 21.3% | 21.8% | 27.2% |
| FCF Margin | 19.8% | 6.0% | 13.6% | 27.8% | 32.3% |
| Diluted EPS Growth | -24.1% | 63.6% | 14.9% | 13.6% | 37.4% |